Severe refractory systemic lupus erythematosus (srSLE) is a clinical state conceptualised as persistent high disease activity despite standard care with glucocorticoids and immunosuppressants.

New and updated clinical guidelines released today provide comprehensive, evidence-based recommendations for the management of axial spondyloarthritis (axSpA) for both adults and children.

JAMA Network Open has publshed that a simple 2-gene blood test may aid the earlier diagnosis of Kawasaki disease in children with febrile illnesses. 

Biomarker interest has grown considerably in the last 2 decades, owing to advances in genetics, imaging, protein, and multiomics. Despite these advances, biomarkers as the predictive holy grail of RA therapeutics and prognostication have not yet advanced beyond rheumatoid serologies and C-reactive protein (CRP).

A comprehensive JAMA review synthesizes current evidence on the epidemiology, pathophysiology, clinical evaluation, and treatment of nonspecific low back pain, drawing on 108 publications identified from a PubMed search (2005–2026) and the most recent guidelines from the WHO, ACP, and NICE. While the primary audience is generalists, the review carries important implications for rheumatologists who regularly encounter patients with back pain in the context of inflammatory arthritis, axial spondyloarthritis, and other systemic diseases.

Dr. Jack Cush reviews the news, journal reports and best ways to review EULAR 2026.

On the final day of EULAR 2026, Mukhtyar et al (on behalf of a large international task force) presented the updated EULAR recommendations for management of polymyalgia rheumatica (PMR), giant cell arteritis (GCA), and Takayasu arteritis (TAK). There were 5 overarching principles and 12 recommendations.

It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.

Much of the meeting came for the next CAR T readout. AB-101 drew attention for a different reason. It depletes B cells by a completely different route.

The last day in London was exciting as both the Late-Breaking abstracts and new EULAR guidelines were presented.